哮喘是临床常见慢性呼吸道疾病,近年来,发病率呈明显上升趋势,已成为严重公共卫生问题而受到世界极大关注。2002年,GINA(全球哮喘防治倡议)进一步强调早期吸入糖皮质激素的重要性和安全性[1],但在吸入疗法应用的过程中往往受到很多因素影响而导致失败,现将影响患者吸入治疗原因分析如下。 Asthma is a common chronic respiratory disease in clinical practice. In recent years, the incidence has been on the rise. It has become a serious public health problem and has drawn great attention from the world. In 2002, GINA (Global Asthma Prevention Initiative) further emphasized the importance and safety of early inhaled glucocorticoid [1], but it is often influenced by many factors in the course of inhalation therapy, which will affect the patient’s inhalation therapy The reason is analyzed as follows.